Online inquiry

IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3420MR)

This product GTTS-WQ3420MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets HGF gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000601.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3082
UniProt ID P14210
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3420MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1317MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ9914MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA KB-003
GTTS-WQ9712MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ5052MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CaCP-29
GTTS-WQ5857MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ5978MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CLLB8
GTTS-WQ7997MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ25MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 2130
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW